Lovenox Injection
Product Images NDC 0075-8014

Product Visual Gallery

This gallery contains 32 technical images submitted to the FDA as part of the official labeling for Lovenox (NDC 0075-8014). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sanofi-aventis U.s. Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lovenox Premier 01

FDA Label Image

Lovenox Premier 02

FDA Label Image

Lovenox Premier 03

FDA Label Image

Lovenox Premier 04

FDA Label Image

Lovenox Premier 05

FDA Label Image

Lovenox Premier 06

This is not-available as the provided text seems to be a list of chemical symbols and formulas, and it is not clear what context or chemical compound it may refer to.*

FDA Label Image

Lovenox Premier 07

FDA Label Image

Lovenox Premier 08

This text seems to be a table illustrating the Relative Risk and the No. of hemorrhagic transformations with patients of different subgroups undergoing treatment for some medical condition. The medical condition is not available as the text seems to be incomplete. The subgroups mentioned are: female, anterior infarct location, other infarct locations, diabetes, prior strokes, fibrinolytic agent: Streptokinase, and symptomatic intracranial hemorrhage. The text indicates that Enoxaparin is better at reducing hemorrhagic transformation when compared to other treatments mentioned.*

FDA Label Image

Lovenox Premier 09

The text is not-available.*

FDA Label Image

Lovenox Premier 10

FDA Label Image

Lovenox Premier 11

FDA Label Image

Lovenox Premier 12

FDA Label Image

Lovenox Premier 13

FDA Label Image

Lovenox Premier 14

FDA Label Image

Lovenox Premier 15

FDA Label Image

Lovenox Premier 16

FDA Label Image

Lovenox Premier 17

FDA Label Image

Lovenox Premier 18

FDA Label Image

Lovenox Premier 19

FDA Label Image

Lovenox Premier 20

FDA Label Image

Lovenox Premier 21

FDA Label Image

Lovenox Premier 22

FDA Label Image

Lovenox Premier 23

This text is too short to generate a useful description. It only includes common words that do not provide specific information about any particular product or context. Therefore, the resulting description would be generic and not helpful.*

FDA Label Image

Lovenox Premier 24

FDA Label Image

Lovenox Premier 25

Lovenax® is a medication that contains 3mg of enoxaparin sodium injection derived from porcine intestinal mucosa. It is administered via subcutaneous injection, and dosage information can be found in the package insert. It is important to keep this medication out of the reach of children and store it at 25°C (77°F). Lovenox® is a registered trademark of Premier Healthcare Alliance, LP., used under a license by sanofi-aventis U.S. LLC. This medication comes in a single dose syringe with an automatic safety device and is for subcutaneous injection only. Activation of the safety system occurs after completion of the injection. The needle shield should not be replaced after injection. Serialization information is also available.*

FDA Label Image

Lovenox Premier 26

Lovenax® is a prescription medicine that contains enoxaparin sodium injection derived from porcine intestinal mucosa. It is available in single dose syringes with automatic safety device for subcutaneous injection. Each syringe contains 40mg of enoxaparin sodium injection in water for injection. It is important to keep it out of reach of children and store at a temperature of 25°C with some permitted excursions. The dosage and administration may vary, so it is recommended to check package insert instructions before use. The text contains additional information about the safety device of the syringe and a reserved area for serialization.*

FDA Label Image

Lovenox Premier 27

Lovenox® is a porcine-derived medication used to prevent blood clots. The medication is delivered subcutaneously via a single-dose syringe that comes with an automatic safety device. Each syringe contains 60mg of enoxaparin sodium injection. The dosage information and administration can be found in the package insert. The product should be kept out of reach of children and stored at a controlled room temperature.*

FDA Label Image

Lovenox Premier 28

Lovenox® (enoxaparin sodium injection) is a medication that comes in single-dose syringes with an automatic safety device for subcutaneous injection. Each syringe contains 8mg of enoxaparin sodium injection derived from porcine intestinal mucosa in Water for Injection. The correct use and dosage of the medication can be found on the label of the product. Warning is given to keep the product out of the reach of children and store it at the appropriate temperature. Activation of the safety system needs to be done only after confirmation of the correct usage by a registered healthcare practitioner, and the safety system should not be sterilized. A specific area is reserved for serialization of the product.*

FDA Label Image

Lovenox Premier 29

Lovenox® is a prescription medicine that contains enoxaparin sodium derived from porcine intestinal mucosa in Water for Injection. It is administered through subcutaneous injection. The syringe comes with automatic safety device and each syringe contains 100mg enoxaparin sodium injection. Dosage and administration instructions are provided on the package insert. The product must be stored at 25°C with permitted excursions to 15-30°C. The warning message states that the product must be kept out of reach of children. The text also contains other important information related to the use of the product.*

FDA Label Image

Lovenox Premier 30

Lovenox® is a medication used for subcutaneous or intravenous injection. It comes in a multiple-dose vial of 3mL, with each 0.1mL of the injection containing 10mg enoxaparin sodium derived from porcine intestines, and 1.5mg benzyl alcohol. The package insert contains dosage information and directions for use. Lovenox® should be stored at 25°C (77°F) with excursions permitted to 15-30°C (59-86°F). The multiple-dose vials should not be stored for more than 78 days after the first use. Lovenox® is manufactured by Sanofi-Aventis US, LLC, with the trademark registered by PremierProRx®.*

FDA Label Image

Lovenox Premier 31

Lovenox® is a subcutaneous injection used for medicinal purposes containing 120mg/0.8ml of enoxaparin sodium. The drug is supplied in single-dose syringes with automatic safety devices. The package insert elaborately explains the dosage and administration of the drug. The warning label on the syringe recommends it to be kept out of reach of children. It should be stored at room temperature between 15-30°C. The syringe should not be reused, and the safety system should not be sterilized. The use of the safety system may cause minimal fluid splatter, so it should be activated away from the user for optimal safety. The Datamatrix code on the packaging is reserved for serialization.*

FDA Label Image

Lovenox Premier 32

Lovenox® is an enoxaparin sodium injection used for subcutaneous administration. Each syringe consists of 150mg of enoxaparin sodium injection derived from porcine intestinal mucosa. It is packaged in Single Dose Syringes with an Automatic Safety Device for subcutaneous injection. The package insert provides dosage and administration information, and each 0.02mL graduation equals 3mg enoxaparin sodium injection. The safety system should only be activated after injection, and activation of the system can cause splatter. Replacement of the needle shield after injection is not recommended.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.